Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCDC39 antisense RNA 1 (non-protein coding) (CCDC39-AS1)
- Target
- CCDC39-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA
01
Overview
CCDC39 antisense RNA 1 (CCDC39-AS1) is a long non-coding RNA gene located on chromosome 3 that functions as an antisense regulator of the CD39 (ENTPD1) gene by modulating its mRNA levels post-transcriptionally. It is enriched in regulatory T cells and Th17 cells from individuals with Crohn’s disease, and its inhibition using antisense oligonucleotides can restore CD39 expression and ameliorate disease activity in animal models. The molecule does not code for a protein and is not considered a traditional drug target, but represents a novel therapeutic target for RNA-based interventions in immune regulation disorders
- Other names
- CCDC39-AS1CCDC39 antisense RNA 1CCDC39 antisense RNA 1 (non-protein coding)
02
Mechanism of action
For experimental oligonucleotide inhibitors, the mechanism of action is silencing of CCDC39-AS1, which upregulates CD39 expression, restoring immune regulation
03
Biological functions
Regulation of gene expression (post-transcriptional modulation of CD39/ENTPD1)Potential roles in neuronal identity and ciliary function (based on expression patterns)
04
Disease associations
Crohn’s disease (via regulation of CD39, which controls immune homeostasis)Currarino syndrome (gene-disease association, but mechanistic link unclear)Possibly other chronic inflammatory conditions linked to CD39 dysfunction
05
Safety considerations
No specific safety concerns are documented, but general concerns with RNA-targeting therapies (off-target effects, immunogenicity) would apply
06
Interacting drugs
FANA-CD39-AS
07
Biomarkers
Expression levels of CCDC39-AS1 in Treg and Th17 cells are associated with disease activity in Crohn's disease and potentially serve as disease biomarkers
Beyond the preview
Go deeper on CCDC39 antisense RNA 1 (non-protein coding) (CCDC39-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCDC39 antisense RNA 1 (non-protein coding) (CCDC39-AS1).